Andrew Miller Joins Elucid as Chief Technology Officer

 Elucid Inc. has hired Andrew Miller as its chief technology officer (CTO) to lead the technological strategy and oversee the engineering team’s execution.

Elucid’s software is the only U.S. Food and Drug Administration (FDA)-cleared non-invasive tool able to accurately characterize arterial plaque, simulating what pathologists would see under a microscope and establishing a histologic ground truth. Elucid is also pursuing an indication for FFRCT, uniquely derived from its PlaqueIQ technology, to non-invasively measure coronary blockages and the extent of ischemia.
 
“We’re thrilled to welcome Andrew as CTO. He has an incredible technological skillset and proven track record in building high-performing technology teams across numerous successful organizations throughout his career,” Elucid CEO Blake Richards said. “A true thought leader, his expertise executing vision and growing organizations will help propel Elucid as we grow commercially and realize the next phase of our mission to provide comprehensive and accurate clinical insights that enable precision healthcare for vascular disease.”
 
Miller is a health technology veteran with an acumen for transforming startups and growth-stage companies into mature organizations. His proven history of building diverse, high-performing organizations has led to profitable business and acquisition. Miller most recently worked for Engooden Health as CTO and chief information security officer, responsible for delivery of technology solutions and infrastructure supporting the SaaS and service-based organization in its mission to redefine chronic care management. Prior to his leadership role at Engooden, Miller served as vice president of engineering for Curaspan, a naviHealth company. Previously, he held roles at Oracle as a senior leader in its Health Sciences division, and Phase Forward, among others.
 
Miller joins recent hires Dr. Todd Villines, chief medical officer, and Scott Burger, chief commercial officer, on Elucid’s leadership team.
 
“Elucid offers an exciting opportunity that allows me to leverage my experience and skills to work with the talented team already assembled to achieve our goals,” said Miller. “Along with Blake and the rest of the leadership team, I am ready to roll up my sleeves and ensure the company’s groundbreaking technology is developed and advanced in a way that fits seamlessly into physician workflow in the most elegant and useful way possible to help solve one of the biggest challenges facing healthcare today.”
 
Elucid is a Boston-based medical technology company dedicated to bringing precision patient care, as currently practiced in oncology, to cardiology. Its AI-powered imaging analysis software, PlaqueIQ, is designed to deeply understand the biology of cardiovascular disease. The only FDA-cleared analysis software that objectively quantifies plaque morphology based on actual biology (validated against tens of thousands of tissue samples), PlaqueIQ equips physicians with critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke. The Elucid Plaque Analysis software is available for commercial use in the United States and South Korea.